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Abstract 
Background: RNA interference (RNAi), which has facilitated functional characterization of mosquito neural develop‑
ment genes such as the axon guidance regulator semaphorin-1a (sema1a), could one day be applied as a new means 
of vector control. Saccharomyces cerevisiae (baker’s yeast) may represent an effective interfering RNA expression sys‑
tem that could be used directly for delivery of RNA pesticides to mosquito larvae. Here we describe characterization 
of a yeast larvicide developed through bioengineering of S. cerevisiae to express a short hairpin RNA (shRNA) targeting 
a conserved site in mosquito sema1a genes.
Results: Experiments conducted on Aedes aegypti larvae demonstrated that the yeast larvicide effectively silences 
sema1a expression, generates severe neural defects, and induces high levels of larval mortality in laboratory, simu‑
lated‑field, and semi‑field experiments. The larvicide was also found to induce high levels of Aedes albopictus, Anoph-
eles gambiae and Culex quinquefasciatus mortality.
Conclusions: The results of these studies indicate that use of yeast interfering RNA larvicides targeting mosquito 
sema1a genes may represent a new biorational tool for mosquito control.
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Background
The use of larvicides, chemical or microbial agents that 
kill mosquito larvae in the aquatic habitats in which they 
breed, is a key component of integrated mosquito control 
programmes. Aedes mosquitoes, the primary vectors of 
dengue, yellow fever, chikungunya and Zika viruses, lay 
eggs in water-holding containers located in urban areas 
[1], and these containers are readily treated with larvi-
cides. Culex mosquitoes, the principle vectors of West 
Nile virus and lymphatic filariasis [2, 3], are also suscepti-
ble to larvicides, which are used to treat the catch basins 
in which the mosquitoes often breed [4]. When used in 
addition to insecticide-treated nets (ITNs) and indoor 
residual spraying (IRS), larviciding is cost-effective for 
control of Anopheles (malaria vector) mosquitoes in 
urban settings in which breeding sites are few, fixed and 
findable [5]. Due to increases in insecticide resistance to 
existing pesticides and heightened concerns for unin-
tended adverse effects of pesticides on non-target organ-
isms, new larvicides to combat existing and emerging 
mosquito-borne illnesses must be identified. For exam-
ple, Bacillus thuringiensis israelensis (Bti), methoprene 
briquettes, and granular formulations of temephos are 
often used to treat Aedes breeding sites [6–9], but resist-
ance to these pesticides is emerging [10–16]. Further-
more, methoprene can be toxic to invertebrate non-target 
species [7], and regulatory approval for temephos was not 
renewed in the USA in 2015 [17]. Pyrethroid resistance in 
Culex pipiens complex mosquitoes is a global problem, 
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and high levels of resistance have been observed in larvae 
collected in the field (reviewed in [18]). High levels of Bti 
resistance have also been observed in C. pipiens larvae 
[19]. Furthermore, although ITNs and IRS have been the 
backbone for malaria vector control, resistance to insec-
ticides used in these applications is an increasing prob-
lem [20], and neither intervention can combat Anopheles 
mosquitoes that bite or rest outdoors [20].
Ingested double-stranded RNA (dsRNA) molecules 
may represent a new class of species-specific insecti-
cides [21]. RNA interference (RNAi) has been applied for 
functional characterization of mosquito neurodevelop-
ment genes, including the analysis of Ae. aegypti sema1a 
gene function in embryos and larvae [22–24]. Microin-
jection of custom synthetically synthesized small inter-
fering RNAs (siRNAs) targeting the Ae. aegypti sema1a 
gene demonstrated that embryonic silencing of this gene 
results in multiple nerve cord phenotypes in embryos 
[22]. Delivery of siRNA to Ae. aegypti larvae using chi-
tosan nanoparticles demonstrated that Sema1a also 
plays key roles in the developing larval nervous system 
[24]. Loss of sema1a function in larvae results in defec-
tive olfactory receptor neuron targeting, as well as pro-
jection neuron defects coincident with a collapse in the 
shape and structure of the antennal lobe and individual 
glomeruli [24]. Larval silencing of sema1a also results in 
optic lobe defects, including visual sensory neuron tar-
geting defects and improper formation of the retinotopic 
map [23]. In addition to pursuing functional characteri-
zation of neurodevelopmental genes such as sema1a, we 
recently began to examine the potential for translating 
RNAi technology to the field for mosquito control. To 
this end, we have pursued large-scale screens for siR-
NAs that target genes required for Ae. aegypti [25] and 
An. gambiae [26] larval survival. A subset of the siRNAs/
genes screened, including siRNA larvicide 460, the sub-
ject of our present investigation, were assessed due to the 
conservation of the target sequences for these siRNAs in 
multiple vector mosquito species. Given the larvicidal 
activity of siRNA 460 and the conservation of its target 
site in mosquito sema1a genes (see below), a gene that 
we had coincidentally studied in previous investigations 
[23, 24], we decided to pursue detailed characterization 
of this larvicide. Due to the high degree of conservation 
of the target site (a site that had not been targeted in our 
previous studies [22–24]), it was hypothesized that inter-
fering RNA corresponding to this site could function as a 
broad-range mosquito larvicide.
The application of RNAi for mosquito control requires 
cost-effective means of RNA production and an effective 
RNA delivery system. Although chitosan/siRNA effec-
tively silences the Ae. aegypti sema1a gene [23, 24], the 
current inability to mass produce interfering RNAs in a 
cost-effective manner presently hinders the advancement 
of this technology as a means of controlling mosquitoes 
in the field. In an effort to develop an economical means 
of producing RNAi larvicides, as well as a mechanism for 
field delivery of these larvicides to mosquitoes, we have 
begun to engineer Saccharomyces cerevisiae (baker’s 
yeast) strains that express short hairpin RNA (shRNA) 
corresponding to larval lethal genes identified in the 
siRNA screens [25, 26]. Use of yeast, which is readily 
consumed by mosquito larvae, facilitates cost-effective 
synthesis of interfering RNA, which is produced through 
yeast cultivation [27]. Our initial studies focused on char-
acterization of yeast strains that produce shRNAs which 
selectively targeted either Ae. aegypti [25, 26] or An. gam-
biae [25, 26] mosquito larvae. In this study, S. cerevisiae 
was engineered to express shRNA corresponding to the 
conserved siRNA 460 mosquito sema1a target site, a site 
that is not known to be conserved in non-target organ-
isms. The results of this investigation indicate that this 
yeast larvicide functions as a broader-based mosquito 
insecticide that kills Ae. aegypti, Ae. albopictus, Cx. 
quinquefasciatus and An. gambiae larvae, but that does 
not impact non-target arthropods. This larvicide may 
represent a new intervention for the biorational control 
of multiple species of disease vector mosquitoes.
Methods
Animal rearing
Aedes aegypti Liverpool-IB12 (LVP-IB12) strain mos-
quitoes, Ae. albopictus Gainesville strain (from the NIH 
Biodefense and Emerging Infections Research Resources 
Repository, NIAID, NIH (BEI Resources)  strain MRA-
804, Manassas, VA), Cx. quinquefasciatus JHB strain (BEI 
Resources  strain  NR-43025) and An. gambiae G3 strain 
(BEI Resources  strain  MRA-112) mosquitoes were used 
in this investigation. Mosquitoes were maintained gener-
ally as described previously [28], except that sheep blood 
(purchased from HemoStat Laboratories, Dixon, CA, 
USA) was delivered to adult females through a Hemotek 
artificial membrane feeding system (Hemotek Limited, 
Blackburn, UK). The mosquito strains were kept in an 
insectary maintained at 26 °C, at ~80% relative humidity, 
and under a 12 h light:12 h dark cycle with 1 h crepuscu-
lar periods at the beginning and end of each light cycle.
Larval soaking experiments
siRNA #460 was discovered in an siRNA screen for mos-
quito larval lethal genes that was conducted as described 
[25, 26]. As noted above, a subset of the siRNAs screened 
corresponded to target sites that were found to be con-
served in mosquitoes using an algorithm developed by 
Scott Emrich (University of Tennesee), which will be 
described elsewhere. Sequences/genes identified using 
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the algorithm were screened if they corresponded to 
genes that are orthologs of D. melanogaster larval lethal 
genes and are expressed throughout Ae. aegypti larval 
development as discussed previously [25, 26]. For the 
screen, custom siRNAs purchased from Sigma-Aldrich 
(St. Louis, MO, USA) corresponded to the follow-
ing target sequences: #460: 5′-AUU AUC GUC GCG 
GUG ACG GAU-3′ in sema1a (AAEL019771; formerly 
AAEL002653) and a control sequence which is not 
present in any of the mosquito species: 5′-GAA GAG 
CAC UGA UAG AUG UUA GCG U-3′ [29]. As previ-
ously discussed [25, 26], the larval soaking screens were 
performed in duplicate using the general methodol-
ogy described by Singh et  al. [30] on 20 first-instar lar-
vae soaked in 0.5 µg/µl siRNA for four hours. Following 
these treatments, the larvae were reared and evaluated 
as described in the World Health Organization (WHO) 
[31] larvicide testing guidelines, and screen data were 
assessed through use of the Fisher’s exact test. All error 
reported in this study corresponds to standard error of 
the mean (SEM).
Generation of yeast larvicide strains, yeast culturing, 
and tablet preparation
Both stable and transiently transformed yeast strains 
corresponding to the control siRNA sequence were gen-
erated previously [25, 26] and used in the present inves-
tigation (control strain sequence information is included 
in Additional file 1). The methodology used to generate 
these control strains [25, 26] was employed for genera-
tion of plasmid-based transient and stably transformed 
sema.460 strains. A DNA oligonucleotide cassette encod-
ing sema.460 shRNA (see sequence in Additional file 1) 
was purchased from Invitrogen Life Technologies (Carls-
bad, CA, USA). For generation of the plasmid-based 
strain, the #460 shRNA expression cassette (which was 
designed to include BamHI and XhoI compatible sticky 
ends to facilitate cloning) was cloned into the multi-
ple cloning site in pRS426 GPD [32], a non-integrating 
yeast shuttle vector marked with URA3. The cassette 
was cloned into the BamH1 and XhoI sites, which placed 
it downstream of the strong and constitutively active 
GPD promoter and upstream of the cyc1 terminator in 
pRS426 GPD [32]. Following confirmation of the clone 
through restriction digestion (with BamH1 and KpnI) 
and sequencing (Additional file  1), the resulting plas-
mid was used for transformation of S. cerevisiae strain 
BY4742 (genotype MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0, 
[33]). Yeast transformants were screened through selec-
tion on SC minimal media lacking uracil. A more detailed 
description of these methods can be found in Mysore 
et al. [34].
For generation of stable sema.460 transformants, DNA 
encoding sema.460 shRNA and the cyc1 terminator was 
ligated downstream of Gal1, a strong inducible pro-
moter [35], to generate the sema.460 expression cassette 
(Additional file 1), which was subsequently inserted into 
the multiple cloning sites of two yeast integrating plas-
mid shuttle vectors, pRS404 and pRS406 [36] (sequences 
for these vectors, which bear TRP1 and URA3 selection 
markers, respectively, are available through Addgene 
[37, 38]). To generate the pRS406 clone, the sema.460 
shRNA-encoding DNA and cyc1 terminator fragment 
were excised with BamH1 and KpnI digestion and gel 
purification from the pRS426 GPD clone described 
above. This fragment was ligated to the Gal1 promoter 
fragment, which was custom-synthesized by Integrated 
DNA Technologies (Coralville, Iowa, USA) and included 
5′ XhoI and 3′ BamHI compatible sticky ends. This 
Gal1 promoter fragment was ligated upstream of the 
sema.460-cyc1 terminator fragment, which retained a 5′ 
BamH1 compatible sticky end. The resulting expression 
cassette, which had 5′ XhoI and 3′ KpnI compatible ends, 
was inserted at the XhoI and KpnI sites in the multiple 
cloning site of pRS406 [36]. To generate the pRS404 [36] 
clone, the Gal1-sema.460-cyc1 terminator expression 
cassette was extracted from pRS406 via restriction diges-
tion with NotI and KpnI and gel purification, then ligated 
into these sites in pRS404 [36]. The two pRS406-sema.460 
and pRS404-sema.460 plasmids, which were verified via 
restriction digestion and sequencing, facilitated integra-
tion of two copies of the sema.460 shRNA expression 
cassette at both the trp1 and ura3 loci in the CEN.PK 
S. cerevisiae strain (genotype MATa/α ura3-52/ura3-52 
trp1-289/trp1-289 leu2-3_112/leu2-3_112 his3 Δ1/his3 
Δ1 MAL2-8C/MAL2-8C SUC2/SUC2, [39]). Selection 
of doubly transformed S. cerevisiae was performed using 
synthetic complete media lacking tryptophan and uracil. 
PCR and sequencing were utilized to further verify inte-
gration of the transgene (sequences are provided in Addi-
tional file 1) at both the trp1 and ura3 loci.
Following yeast strain generation, control [25] and #460 
shRNA expression strains were grown through shake cul-
ture as discussed previously [25]. In summary, the yeast 
strains were grown under standard conditions in syn-
thetic media to an  OD600 of 3.0. For galactose induction 
of the stable transformant strains, yeasts were cultured in 
20 ml SCD medium containing 20 g/l glucose until early 
stationary growth phase, after which time the cells were 
harvested by centrifugation, transferred into 200 ml of 
fresh SCD medium containing 20 g/l galactose and 2 g/l 
glucose, then cultured at 30  °C and 250× rpm for 18 h 
(OD600 ~ 3.0). Dried inactivated yeast tablets were then 
prepared as described [34]. In summary, for preparation 
of each tablet, 40 ml of liquid culture was transferred to 
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50 ml conical tubes and pelleted by centrifugation. The 
pellet was placed in a 70 °C water bath for 5 min to heat-
kill the yeast. The yeast pellet was then transferred to a 
2  ml tube and centrifuged briefly. After removing any 
remaining media from the supernatant, the tubes were 
left open in an incubator or a food dehydrator at 30 °C for 
48 h to evaporate remaining media. The resulting 70 mg 
tablet was either used immediately or stored for up to 
one week in the capped 2 ml tube at −20 °C.
Conduction of larvicide assays in mosquitoes
Laboratory trials
Laboratory larvicide trials were performed in the insec-
tary as described [26]; these assays conformed to WHO 
[31] guidelines, and a more detailed description of these 
procedures is included in [34]. Larvae that consumed 
heat-inactivated control or shRNA #460 interfering RNA 
larvicide tablets were evaluated in parallel in multiple 
biological replicate experiments (see figure legends for 
details), with each biological replicate experiment con-
sisting of at least three replicate containers per condi-
tion. For each container replicate assay, one control or 
experimental tablet was placed in 500  ml plastic cups 
containing 50 ml of distilled water and 20 newly hatched 
first-instar larvae. When larvae reached L4, 300  µl of 
6% w/v liver powder (MP Biomedicals, Solon, OH, USA) 
was provided as a nutritional supplement. Mosquito sur-
vival was monitored daily until all control-treated ani-
mals had emerged as adults. For statistical analysis of 
larval mortality assays, the percentages of mortality from 
larvicide- vs control-treated containers were combined 
from replicate experiments and transformed to arcsine 
values for evaluation with a t-test. Dose-response curves 
were generated as detailed previously [25] using data 
combined from three biological replicate experiments, 
with each biological replicate experiment including four 
replicate containers per condition (one yeast tablet fed 
to 20 larvae in 50  ml of water as discussed above). For 
the tablets used in these assays, yeast expressing control 
interfering RNA was mixed with sema.460 yeast to vari-
ous concentrations to generate the dried inactivated yeast 
tablets. Data from all replicate experiments were pooled 
for analysis.  LD50 values with 95% confidence intervals 
were calculated, as discussed previously [25] and recom-
mended by the WHO [31] larvicide testing guidelines, 
through generation of a log dosage-probit mortality 
regression line using regression analysis in SPSS soft-
ware. The mortality in the control group, which was less 
than 2%, was corrected according to Abottʼs formula [40] 
as recommended [31]. Linear regression analysis was 
performed separately using Microsoft Excel software.
Assessment of F1 progeny of survivors
200 L1 larvae were treated with 10 sema.460 or control 
tablets, which were placed in 1  liter of water. Following 
treatment, adult survivors (F0) were bred, and eggs (F1) 
collected from gravid females were hatched. For each of 
two biological replicates of the above experiment, three 
biological replicate containers, each with 200 larvae, were 
treated with 10 sema.460 or control tablets. The percent-
ages of mortality were combined from replicate experi-
ments and transformed to arcsine values for evaluation 
with ANOVA followed by Tukey’s pairwise comparison.
Individual rearing/feeding experiments
Individual larvae were subjected to larvicide treatment 
using a slightly modified version of the methodology 
described above. First, 4 mg mini yeast pellets were pre-
pared by pelleting 5 ml of stably transformed sema.460 
or control yeast cultured as described above. Pellets 
were then processed as detailed above, except that dry-
ing times were reduced to one day. Individual larvae were 
then placed in a container holding 50 ml distilled water, 
a mini yeast pellet, and 50  µl of 6%  w/v liver powder. 
For each of three replicate experiments, 20 individual 
sema.460-treated and 20 individual control-treated lar-
vae were assessed. Data from replicate experiments were 
combined and assessed through Chi-square analysis.
Simulated field trials
Experiments were performed and analyzed generally as 
described above, but with two modifications. In one set 
of experiments, larvicide trials were conducted using 
100 ml of rainwater (instead of sterile distilled water) that 
had been collected in South Bend, IN, USA, during sum-
mer 2018. Another set of experiments involved the use 
of larvae that had been hatched from the F2 generation 
of an Ae. aegypti strain recently generated from eggs col-
lected in ovitraps in Trinidad, Trinidad and Tobago dur-
ing summer 2018.
Semi‑field trials
Semi-field larvicide trials were performed in an outdoor 
rooftop laboratory in Notre Dame, IN during July and 
August 2018. These assays, which were conducted using 
Ae. aegypti LVP-IB12 strain mosquitoes, conformed to 
the WHO [31] larvicide testing guidelines. The trials were 
performed in a SansBug 1-Person Free-Standing Pop-Up 
Mosquito-Net tent (Hakuna Matata Tents, Ontario, Can-
ada). The mesh in the tents (472 openings/cm) prevented 
the exit of mosquitoes from the test site, as well as the 
entry of macrobiota into the tent while the assays were 
being conducted. The 30-l containers (depth = 46  cm) 
used for these assays were filled with 26  l of water, 20 
larvae, and a single yeast tablet (prepared from control 
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or larvicidal stably-transformed yeast according to the 
methodology used in reference [34] and described above) 
and were covered with mesh to provide a second level 
of containment. Three biological replicate experiments, 
each with three replicate containers per condition, were 
completed. During the testing period, temperatures 
ranged from 13.5 °C to 42.0 °C. The mean daytime tem-
perature during this trial period was 27 °C, and the mean 
nighttime temperature was 23 °C.
Whole mount in situ hybridization 
and immunohistochemistry
The Aae sema1a riboprobe was synthesized according 
to the Patel [41] protocol and utilized to perform in situ 
hybridization experiments on fourth-instar Ae. aegypti 
brains using methodology previously described [24, 42]. 
L4 larvae were fixed for these in situ experiments, which 
were performed in triplicate, just prior to the time that 
treated animals would typically die. Processed brains 
were mounted and imaged using a Zeiss Axioimager 
equipped with a Spot Flex camera. Following imag-
ing, mean gray values (average signal intensity over the 
selected area) were calculated for quantification of digox-
igenin-labeled transcript signals in control versus experi-
mental brains using FIJI ImageJ software. A t-test was 
used to statistically analyze transcript quantification data 
combined from the three experiments.
Immunohistochemical staining experiments were 
performed in triplicate using previously described 
methodology [43, 44]; mAb nc82 anti-Bruchpilot [45] 
(Developmental Studies Hybridoma Bank, University of 
Iowa, Iowa City, Product nc82, which was deposited by 
E. Buchner) and TO-PRO-3 iodide (Molecular Probes, 
Eugene, OR) were used in these experiments. Larvae 
from four replicate containers per condition were fixed, 
processed, and evaluated in each of three biological rep-
licate experiments. Processed brains were mounted and 
then imaged through use of a Zeiss 710 confocal micro-
scope and Zen software, and these images were evalu-
ated through use of FIJI ImageJ and Adobe Photoshop 
CC 2018 software. For quantification of antibody staining 
intensity, mean gray values were calculated as discussed 
previously [46]. In summary, for assessment of mean 
gray values, the average signal intensity for digoxigenin-
labeled transcript signal in control or larvicide-treated 
brains using Adobe Photoshop CC 2018 software. Data 
combined from the three replicate experiments were sta-
tistically analyzed using a t-test.
Toxicity assays in non‑target species
Drosophila melanogaster
The survival of D. melanogaster larvae (from the w118 
stock [47] obtained from the Bloomington Drosophila 
Stock Center, Bloomington, IN, USA) that had fed on 
sema.460 or control interfering RNA yeast was assessed 
using methodology derived from Murphy et  al. [48]. 
These studies were performed at 22  °C under ambient 
laboratory illumination (12  h light: 12  h dark). In these 
assays, one pellet of dried inactivated sema.460 or con-
trol interfering RNA yeast that had been prepared as 
described above was resuspended in 300  µl of water 
and mixed with standard fly food medium at a ratio of 
1:1 by weight. In each of two biological replicate assays, 
the yeast-food mixture was fed to 10 larvae in a 1.5  ml 
Eppendorf tube secured with a cotton stopper. After 
four days, a moistened lab wipe was added to the tube 
to increase humidity and provide a surface for pupation. 
Following pupation, tubes were opened and moved to a 
vial in which adult emergence was assessed. The number 
of adults that emerged from each tube was recorded as 
a measure of survival. Data from two biological replicate 
experiments were combined and assessed using the Fish-
er’s exact test.
Daphnia spp.
Daphnia pulex and Daphnia magna were acquired from 
Carolina Biologicals (Burlington, NC, USA). Toxicity was 
assessed using 10 adults of each species in each of three 
biological replicate assays. These studies were conducted 
at 22  °C under ambient laboratory illumination (12  h 
light: 12 h dark) in COMBO medium containing 0.0001% 
sodium selenium [49]. A single yeast pellet (sema.460 or 
control) was dissolved in 50 ml of distilled water, and 10 
ml of the solution was fed to the animals daily for five 
days. Survival was assessed on a daily basis over a 10-day 
trial period. Survival data from three replicate experi-
ments were combined and assessed with the Fisher’s 
exact test.
Results
S. cerevisiae expressing shRNA corresponding 
to the sema1a gene kill Ae. aegypti larvae
siRNA #460, which corresponds to a conserved target 
sequence in mosquito sema1a genes (Additional file  2: 
Table S1), was uncovered in an Ae. aegypti siRNA soaking 
screen for larval lethal genes [25]. In the screen, siRNA 
#460 induced 75 ± 5% larval death (Fig.  1a, χ2 = 44.17, 
df = 1, P = 3.02E−11 versus control siRNA treatment) fol-
lowing brief soaking treatment of first instar Ae. aegypti 
larvae. Based on the results of the screens, a non-inte-
grating multi-copy yeast shuttle plasmid in which shRNA 
corresponding to the #460 target sequence was placed 
under control of a constitutive promoter, was constructed 
and used to transform S. cerevisiae. Yeast strain #460, as 
well as a yeast strain that expresses a control shRNA with 
no known target site in mosquitoes [25], were used in 
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the preparation of an inactivated dried yeast tablet [34]. 
Larvae which ingested control yeast tablets survived 
(Fig. 1b), but 92 ± 1% of larvae that fed on yeast interfer-
ing RNA #460 died (Fig. 1b, t(13) = 2.17, P = 7.48E−18 ver-
sus control treatment).
Based on the high levels of mortality induced by yeast 
that had been transiently transformed (Fig.  1b), it was 
determined that it would be beneficial to generate yeast 
that are stably transformed with the shRNA #460 expres-
sion cassette. Following generation of a strain bearing 
two stably-integrated copies of the shRNA #460 expres-
sion cassette (hereafter referred to as sema.460), dried, 
heat-inactivated yeast larvicide sema.460 tablets were 
prepared from the strain. Yeast larvicide sema.460, as 
well as a comparable stable transformant strain express-
ing control shRNA (described in reference [25] and here-
after referred to as the control) were fed to Ae. aegypti 
larvae. Yeast larvicide sema.460 induced 93 ± 1% mor-
tality in Ae. aegypti larvae when 20 larvae were reared 
and treated in a single container (Fig.  1c, t(12) = 2.20, 
P = 1.04E−17 versus control yeast treatment). When lar-
vicide activity was assessed in F1 progeny of sema.460-
treated F0 survivors, no significant differences in the 
levels of larval mortality induced by sema.460 were 
observed in the F0 versus F1 generations (Fig. 1f, F = 688, 
df = 3, P = 2.45E−20, sema.460-F0 vs F1 Tukey: P = 0.07). 
In all of these sema.460 experiments (Fig. 1b, c), no dead 
larvae were observed in these containers. In contrast, 
when larvae were reared and treated as individuals, 100% 
of sema.460-treated larvae died (Fig.  1g, χ2 = 155.60, 
df = 1, P = 1.04E−35), and the larval remains could be 
observed in each container for several days. Larvae 
treated with sema.460 larvicide died during the fourth 
instar or as pupae (Fig. 1d). Larval death was linearly cor-
related to the dose of sema.460 fed to the larvae (Fig. 1e; 
control mortality = 1.08 ± 0.33%;  LD50 = 31.3 mg).
Larval consumption of sema.460 yeast larvicide results 
in Aae sema1a silencing and severe defects in the Ae. 
aegypti larval nervous system
As previously reported [24], Aae sema1a transcripts 
are expressed broadly in the brain of L4 larvae (Fig. 2a). 
Quantification of Aae sema1a transcript levels in the 
L4 larval brain of animals fed with control (Fig. 2a) ver-
sus sema.460 (Fig.  2b) dried inactivated yeast larvicide 
tablets confirmed that larval consumption of sema.460 
results in significant silencing of sema1a (Fig  2c; 
82 ± 9% reduction of sema1a transcript was observed; 
t(53) = 2.00, P = 1.57E−57). Based on previous studies [24], 
it was hypothesized that severe neural defects would be 
observed in Ae. aegypti larvae that had consumed yeast 
larvicide sema.460. Larval silencing of sema1a through 
chitosan/siRNA-mediated targeting of alternative sites in 
the Aae sema1a gene [24] resulted in significantly lower 
levels of nc82 antibody staining, which reveals expres-
sion of the active zone marker Bruchpilot (Brp; detected 
by nc82 antibody staining [45]). Similarly, Brp levels were 
significantly reduced (t(43) = 2.01, P = 1.95E−48 versus 
control) in the L4 brains of larvae that had consumed 
sema.460 (Fig. 2e1–e3; 88 ± 9% reduction observed with 
respect to control-treated animals, which are shown in 
Fig. 2d1–d3). These severe neural defects correlated with 
the time of larval death observed in sema.460-treated lar-
vae (Fig. 1d).
(See figure on next page.)
Fig. 1 Silencing Aae sema1a induces larval mortality. a siRNA #460, which corresponds to sema1a, was identified in a screen [25] in which Ae. 
aegypti larvae soaked in 0.5 μg/μl siRNA #460 died (compare to control siRNA‑treated larvae which survived). Screen data from two replicate 
experiments (n = 20 larvae/replicate) were combined and assessed with the Fisher’s exact test. shRNAs corresponding to the #460 or control 
siRNA sequences were expressed in S. cerevisiae from a plasmid (b) or following integration of two copies of the shRNA expression cassettes into 
the S. cerevisiae genome (c). Larval consumption of inactivated dried yeast interfering RNA tablets corresponding to the #460 target sequence 
induced significant Ae. aegypti larval mortality (b, c). Data shown in panels b (n = 12 replicate containers/treatment, each with 20 larvae for a total 
of 240 larvae/treatment) and c (n = 12 replicate containers/treatment, each with 20 larvae for a total of 240 larvae/treatment) were combined 
from three biological replicate experiments and analyzed with t‑tests. For each container replicate in b, c, and all subsequent figures, one 70 mg 
yeast tablet was fed to 20 larvae unless indicated otherwise. d Ae. aegypti larval consumption of inactivated dried sema.460 tablets prepared from 
stably‑transformed strains (which were used for the assays in this panel and all subsequent trial data reported in this investigation) induced death 
during the L4 larval or pupal stages (days 4–8), while larvae that consumed control yeast survived to adulthood. e A dose‑response curve shows 
that larval mortality is linearly correlated (R2 = 0.9835) with the dose of sema.460 provided to larvae. Each point on the graph corresponds to the 
percentage mortality observed in a single container replicate assay performed on 20 larvae (data were compiled from three biological replicate 
experiments). sema.460  LD50 values with upper and lower confidence limits (CL) are shown. f Larvae that survived treatment with sema.460 were 
bred, and the susceptibility of their offspring to sema.460 was assessed. No significant differences in larvicide activity were noted in the F0 vs F1 
generations (for each generation, n = 6 container replicates/condition, each with 200 larvae that were fed with 10 tablets); data were combined 
from two biological replicate experiments and analyzed by ANOVA. g When sema.460‑treated larvae reared as individuals were fed with one 4 mg 
tablet, 100% mortality was observed (all control‑treated individuals survived). Data on a total of 60 individuals/treatment (combined from three 
biological replicate experiments) were analyzed by Chi‑square analysis. The data presented in panels a–c, f and g correspond to mean percentages 
of mortality, with error bars here and in all subsequent figures representing SEM. ***P < 0.001 with respect to control‑treated larvae in all panels
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Yeast larvicide sema.460 induces high levels of larval 
mortality in simulated‑field and semi‑field experiments
The activity of sema.460 was next assessed under condi-
tions that more closely simulate conditions encountered 
in the field. The activity of sema.460 was confirmed in 
insectary experiments that were conducted using rain-
water rather than sterile distilled water (Fig.  3a), with 
82 ± 2% larval mortality observed in sema.460-treated 
animals (t(5) = 2.57, P = 9.13E−05 versus control-treated 
larvae). The activity of sema.460 was also assessed and 
confirmed in insectary experiments conducted on F2 
larvae collected from a newly generated strain of Ae. 
aegypti mosquitoes established from eggs collected in 
Trinidad, Trinidad and Tobago (Fig.  3b). 91 ± 1% lar-
val mortality was observed in sema.460-treated animals 
in these experiments (t(11) = 2.20, P = 3.97E−12 versus 
control-treated larvae). Finally, sema.460 activity was 
assessed in semi-field experiments conducted in an out-
door roof top laboratory. Larger 30-l containers bearing 
26 l of water, a size which better approximates common 
productive Ae. aegypti breeding sites found in the trop-
ics [50], were used in these trials. Although little death 
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Fig. 2 Yeast larvicide sema.460 effectively silences the sema1a target gene and induces severe neural defects in the Ae. aegypti L4 brain. Larval 
consumption of dried inactivated sema.460 tablets results in silencing of sema1a (b), which is normally expressed at high levels throughout the 
L4 larval brain ([24]; control‑treated animal is shown in a for comparison). These results were quantified through analysis of mean gray value 
comparisons of sema.460‑ versus control‑treated larvae (c; n = 53 sema.460‑treated L4 brains; n = 57 control‑treated L4 brains; data are represented 
as average mean gray values in c, as well as d3 and e3). Average mean grey value analyses (compiled from three biological replicate experiments 
with 65 control‑treated larvae in d3 and n = 51 sema.460‑treated larvae in e3) indicated that levels of nc82, which marks synaptic active zones 
(white in d1, e1; red in d2, e2), were significantly reduced in the synaptic neuropil of L4 larvae, while TO‑PRO nuclear staining (blue in d2 and e2) 
levels were not significantly different. ***P < 0.001 with respect to control‑fed larval brains (c, e3, analyzed by t‑test). Representative L4 brains are 
oriented dorsal upward in this figure. Abbreviations: SOG, sub‑esophageal ganglion; SuEG, supra‑esophageal ganglion; LAL, larval antennal lobe; OF, 
olfactory foramen; OL, optic lobe
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was observed in containers in which larvae fed on control 
yeast tablets, 90 ± 1% of larvae in containers treated with 
sema.460 tablets died (Fig. 3c, d, t(8) = 2.30, P = 6.87E−12 
versus control-treated larvae).
sema.460 functions as a broad‑range mosquito larvicide
The sema.460 target site is conserved in multiple spe-
cies of Anopheles mosquitoes, as well as Ae. albopictus 
and Cx. quinquefasciatus, but was not found to be con-
served in the genomes of humans or other non-target 
organisms for which genome sequences are presently 
available, including arthropods other than mosquitoes 
(Additional file 2: Table S1). Based on the conservation of 
this target site in other mosquitoes, it was hypothesized 
that sema.460 would have broad-range mosquito larvi-
cidal activity. As expected, significant larval mortality 
was observed in Ae. albopictus larvae that had consumed 
sema.460 tablets, with 93 ± 1% of larvae dying (Fig.  4a, 
t(8) = 2.30, P = 2.26E−12 with respect to control-treated 
larvae). Similarly, larval consumption of dried inacti-
vated yeast larvicide sema.460 tablets induced 90 ± 1% 
larval mortality in An. gambiae (Fig.  4b, t(11) = 2.20, 
Fig. 3 Simulated‑field and semi‑field evaluation of sema.460 activity in Ae. aegypti. a Activity of sema.460 was confirmed in trials conducted in 
rainwater. Data shown were compiled from two biological replicate experiments and represent results from six container assays, each with 20 
larvae for a total of 120 larvae assessed/condition. b Activity was also confirmed in F2 larvae from a Trinidad field strain. Data were compiled from 
three replicate experiments conducted on a total of 240 larvae/condition that were assessed in 12 containers, each with 20 larvae. c The activity 
of sema.460 was also confirmed in semi‑field trials. Data were compiled from three biological replicate experiments conducted on a total of 180 
animals/treatment in nine replicate containers with 20 larvae each. d Semi‑field trials were conducted in a contained outdoor roof top laboratory. 
Mean percentages of larval mortality are shown in a–c. Data in a–c were analyzed with t‑tests; ***P < 0.001 when compared with control‑fed larvae
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P = 1.93E−17 versus control treatment). Finally, sema.460 
induced 90 ± 1% mortality in Cx. quinquefasciatus 
(Fig.  4c, t(11) = 2.20, P = 1.76E−16 versus control treat-
ment). These data support the hypothesis that sema.460 
is a broad-range mosquito larvicide. Although sema.460 
induces death in a variety of mosquito species, it has 
no larvicidal activity in D. melanogaster, a dipteran 
insect (Fig.  5a, χ2 = 1.598, df = 1, P = 0.21) in which the 
sema.460 target site was not identified (Additional file 2: 
Table S1). Likewise, D. pulex (Fig. 5b, χ2 = 0.4549, df = 1, 
P = 0.5) and D. magna (Fig. 5c, χ2 = 0, df = 1, P = 1), two 
distantly related aquatic arthropods that are often used 
in U.S. Environmental Protection Agency (EPA) toxic-
ity assays [51], lack the sema.460 target site (Additional 
file  2: Table  S1) and survived following consumption of 
sema.460.
Fig. 4 sema.460 yeast kills larvae of multiple mosquito species. Oral consumption of sema.460 results in high levels of Ae. albopictus (a), An. 
gambiae (b) and Cx. quinquefasciatus (c) larval mortality. a A total of 180 Ae. albopictus larvae were assessed in nine replicate containers/condition, 
each with 20 larvae. b 240 An. gambiae larvae were evaluated in 12 replicate containers/condition, each with 20 larvae. c 240 Cx. quinquefasciatus 
larvae were assessed in 12 replicate containers/condition with 20 larvae in each container. The results shown in this figure were compiled from 
three biological replicate experiments conducted on each mosquito species. Data shown represent mean larval mortalities. ***P < 0.001 in 
comparison to control‑fed larvae (t‑test)
Fig. 5 sema.460 is not toxic to three non‑target arthropods. a Oral consumption of sema.460 by D. melanogaster larvae did not impact survival 
through adult emergence (a total of 20 larvae/treatment were assessed in two biological replicate experiments, each conducted with 10 larvae/
treatment). b Consumption of sema.460 by D. pulex did not impact adult survival (30 animals/treatment were evaluated in three biological 
replicate experiments in which 10 animals/treatment were assessed over a 10‑day trial period). c Likewise, sema.460 was not toxic to D. magna (30 
animals/treatment were evaluated in three biological replicate experiments in which 10 animals/treatment were assessed for a 10‑day trial period). 
Control groups in all of these assays were treated with yeast prepared from yeast expressing control shRNA. Survival data compiled from two (a) 
or three (b, c) replicate experiments and analyzed with the Fisher’s exact test indicated that there were no significant differences in the survival of 
sema.460‑ and control‑treated organisms. Data shown represent mean percentages of survival
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Discussion
Yeast larvicide sema.460, a promising new tool 
for broad‑based mosquito control
In this study, we provide detailed characterization of 
yeast larvicide sema.460, which may represent a new 
tool for broad-based mosquito control. Like other siR-
NAs that were previously designed to silence sema1a [23, 
24], yeast interfering RNA larvicide sema.460 induces 
significant larval neural defects (Fig. 2) which, based on 
their close correlation with the onset of death (Fig.  1d), 
are presumably a primary cause of this death. However, 
sema.460, unlike the siRNAs that were previously used to 
assess the function of sema1a [23, 24], has a target site 
that is conserved in multiple mosquito species (Addi-
tional file  2: Table  S1). Aedes aegypti and An. gambiae, 
which were previously shown to be susceptible to yeast 
interfering RNA larvicides targeting other larval lethal 
genes [25, 26], display high levels of mortality follow-
ing treatment with sema.460 (Figs.  1, 4b). Additionally, 
the results of this study indicate that Ae. albopictus and 
Cx. quinquefasciatus larvae are also susceptible to yeast 
interfering RNA larvicides, with sema.460 inducing high 
levels of mortality in both species (Fig. 4a, c). While the 
sema.460 target site is conserved in multiple mosquito 
species, a lack of conservation of this site outside of mos-
quitoes (Additional file 2: Table S1), suggests that it could 
offer a new means of mosquito control that has little, if 
any, impacts on non-target organisms, including other 
arthropods. In support of this, sema.460 was not toxic to 
D. melanogaster, another dipteran insect, or D. pulex and 
D. magna, two distantly related aquatic arthropods that 
are recommended by the EPA for evaluation of the toxic-
ity of substances to freshwater organisms [51] (Fig. 5).
As a member of a new class of larvicides, sema.460 
could help combat resistance to existing insecticides, an 
ever-growing problem [10–16, 52]. Moreover, through 
our efforts to build an arsenal of interfering RNA lar-
vicides ([25, 26], this study), we are working to combat 
resistance that could potentially develop due to a muta-
tion in any one shRNA target site. A small percentage 
of sema.460-treated animals survive when the larvae 
are reared in a group of 20 animals (Fig.  1b, c). When 
these larvae are bred, the F1 progeny of the survivors 
are susceptible to sema.460 (Fig. 1f ), suggesting that the 
F0 larvae which survived treatment were not resistant 
to sema.460 larvicide or RNAi in general (a trait which 
would have been inherited by their F1 progeny). Instead, 
it seems likely that survivors of sema.460 treatment may 
be eating other dead larvae in the container rather than 
yeast. In support of this, when 20 or more larvae are 
treated with sema.460 in a single container, dead lar-
vae are rarely observed in these containers. However, 
when larvae were reared as individuals and treated with 
sema.460, 100% of larvae died (Fig. 1g), and the remains 
of these larvae were visible for several days, providing 
further evidence that F0 larvae of the LVP-IB12 strain 
used in these experiments do not harbor resistance to 
RNAi or the sema.460 larvicide. We are in the process 
of assessing in greater detail whether resistance to yeast 
interfering RNA larvicides can develop in Ae. aegypti 
over time.
Potential benefits of a yeast delivery system 
for RNAi‑based mosquito control
Saccharomyces cerevisiae may provide an excellent sys-
tem for both cost-effective interfering RNA production 
and delivery of the RNA to mosquito larvae. As recently 
discussed [27], S. cerevisiae, which lacks both Dicer and 
Argonaute [53] and therefore a functional endogenous 
RNAi system, may have initially caused it to be over-
looked as a system for producing interfering RNA mol-
ecules. However, this deficiency in RNAi machinery 
could potentially promote the accumulation of bioengi-
neered interfering RNA in yeast, making it an excellent 
system for interfering RNA production. Similarly, studies 
in plants have indicated that dsRNAs can be more stably 
produced in chloroplasts, a cellular component which 
also lacks functional RNAi machinery [54]. Expression 
of dsRNA targeting potato beetles in the chloroplasts 
of potato plants, as opposed to the nuclear genome, led 
to accumulation of dsRNA at high levels and increased 
potato beetle mortality [54]. These results, which have 
sparked interest in use of the chloroplast genome to 
express dsRNAs targeting agricultural pests [54], may 
similarly apply to yeast and could explain why this sys-
tem silences mosquito genes so effectively ([25, 26], this 
study).
As discussed in a recent review [27], genetic engi-
neering of S. cerevisiae facilitates affordable synthesis of 
shRNA, which is produced as the yeast is cultivated. Yeast 
serves not only as an shRNA production system, but also 
as a strong mosquito larval odorant attractant [24] and 
a common source of larval nutrition in laboratory-bred 
mosquitoes, and so the production system can serve 
directly as the larval bait. Yeasts have been cultivated 
worldwide since ancient times, suggesting that yeast lar-
vicides could be produced easily at many sites across the 
globe. Moreover, S. cerevisiae, a non-toxic product that 
is used frequently in beverage and food preparation and 
sold as a dietary supplement [27], may be more readily 
accepted than traditional chemical pesticides. Interest-
ingly, our work has demonstrated that heat-inactivated 
yeast in which interfering RNA has been expressed kills 
larvae as effectively as live yeast [25, 26]. This is use-
ful, particularly if there were to be interest in the use of 
these larvicides for treatment of drinking water, as there 
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would be no further growth of the inactivated microbes 
in treated water. Although it is anticipated that yeast lar-
vicide products will be safe, particularly with respect to 
conventional pesticides [55], it will of course be critical to 
perform toxicology tests on commercially-ready formu-
lations, and these formulations will need to be reviewed 
by the appropriate regulatory bodies in the countries of 
intended use. The United States EPA recently approved 
an RNAi-based agricultural pesticide tool [17], and it is 
likely that additional registry applications will follow this 
one. However, the use of genetically modified yeast, even 
if it is dead, will need to be approved in each country of 
intended use. This will be a challenge, as some countries 
may lack a regulatory body equivalent to the EPA to eval-
uate this new technology.
The results of this investigation demonstrated that 
sema.460 induced high levels of larval mortality in both 
simulated-field and semi-field experiments (Fig. 3). These 
results suggest that it will be worthwhile to pursue fur-
ther research and development in an effort to bring yeast 
larvicide technology to market. Critical areas for further 
development include optimization of RNA expression in 
S. cerevisiae, commercial-scaling of yeast larvicide pro-
duction, and testing of commercially appropriate meth-
ods of yeast drying that preserve interfering RNA activity. 
It will also be important to identify encapsulating agents 
that will enhance yeast stability in various environmental 
conditions that might be encountered both prior to and 
during its use, and which may also serve to permit the 
controlled and extended release of yeast interfering RNA 
larvicides [27]. In preparation for the successful launch 
of field trials, it may also be useful to develop a variety 
of different formulations. For example, a variety of dif-
ferent Bti formulations, including tablets, granules, bri-
quettes, powders, and flowable concentrates have been 
developed for control of mosquito larvae in various habi-
tats [56]. Like Bti [56], it could also be helpful to vary the 
buoyancies of these formulations, which could facilitate 
the targeting of different species of disease vector mos-
quitoes that live in a wide variety of different habitats. 
The genetic tractability of S. cerevisiae, a genetic model 
organism, combined with the long and rich history of 
using yeast in food and pharmaceutical industries will 
undoubtedly help to advance development of this prom-
ising new technology for combating mosquitoes [27]. As 
formulation development, the piloting of scaled fermen-
tation, and field-testing progress, it will also be critical to 
assess the relative cost of this technology in comparison 
to other larvicides.
Beyond Ae. aegypti: Prospects for using yeast‑based 
interfering RNA larvicides for control of other disease 
vector mosquitoes
The results of this investigation suggest that in addi-
tion to Ae. aegypti, yeast interfering RNA larvicides may 
also be used for the control of multiple disease vector 
mosquitoes (Fig.  4). While dried inactivated yeast pel-
lets work well in laboratory assays, further work will be 
required to assess the most optimal formulations to be 
used for control of each species in the varied habitats in 
which it resides. The spatial distributions of Ae. aegypti 
and Ae. albopictus, both of which vector dengue, Zika, 
and chikungunya viruses, frequently overlap [57, 58]. 
The potential for controlling both species with a single 
interfering RNA larvicidal agent is advantageous, as the 
two species can lay eggs in the same container breeding 
sites [57]. Thus, ready-to-use inactivated yeast tablets, 
which were designed to facilitate the treatment of con-
tainers near consumer homes, might represent a means 
of controlling both species. Moreover, Hapairai et al. [25] 
demonstrated in laboratory trials that inactivated yeast 
tablets can attract gravid Ae. aegypti females to lay eggs 
in treated containers, and this may also be true for Ae. 
albopictus females. This feature is useful, as it may help 
to ensure that Aedes females, which are known to exhibit 
skip-oviposition behavior [59], will prefer to lay eggs in 
treated containers.
The results of this study also demonstrate that yeast 
interfering RNA larvicide technology may offer a new 
means of controlling Culex mosquitoes (Fig.  4c). The 
existing global disease burden of lymphatic filariasis [3], 
recent spread of West Nile virus across the continental 
United States, and reported resistance to existing lar-
vicides [52] make the development of new larvicides 
for control of Culex pipiens complex mosquitoes a vital 
necessity. Larvicides for control of Culex mosquitoes are 
often used to treat stormwater catch basins, which are 
known to be important breeding sites for Culex mos-
quitoes in urban and suburban regions [60–62]. For tar-
geting Culex mosquitoes, it may therefore be useful to 
develop formulations of yeast larvicides that are capable 
of persisting in catch basins. Nasci et al. [4], who recently 
evaluated the efficacy of a variety of different larvicides 
and formulations for treatment of stormwater catch 
basins functioning as Culex breeding sites, concluded 
that monthly re-treatments of these basins with granular 
larvicide formulations may be optimal. The authors spec-
ulate that tablets and briquettes may be prone to being 
buried in sediment or flushed out of the catch basin; they 
suggest that granular formulations may disperse more 
readily and be less prone to being buried or flushed out 
of the catch basins. Thus, for control of Culex, it may be 
useful to develop granular and buoyant formulations of 
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yeast larvicides for optimized catch basin treatment. 
Such formulations may also be appropriate for treatment 
of large drums and barrels, typical water storage contain-
ers in the tropics that also function as some of the most 
productive Aedes breeding containers [50].
As discussed above, larviciding is an integral part of 
integrated Aedes [1] and Culex [2] mosquito control 
programmes. Additionally, in the first half of the 20th 
century, larval source management (LSM) was also a 
broadly applied and highly effective method for control 
of anopheline mosquitoes and malaria prevention [63]. 
However, IRS with dichlorodiphenyltrichloroethane 
(DDT) replaced many LSM programmes in the latter part 
of the 20th century [63]. IRS and ITNs continue to be the 
backbone for malaria vector control, but due to increas-
ing problems with resistance to the insecticides used in 
these applications, there is renewed interest in expand-
ing larval control programmes, which can reduce the 
number of mosquitoes that enter homes and the number 
of outdoor-biting mosquitoes for prevention of residual 
transmission [63]. The WHO determined that larvicid-
ing is cost-effective for malaria control in urban settings 
where vector breeding sites are few, fixed, and findable, 
and when it is used as a supplement to ITNs and IRS [5]. 
If larvicide programmes for control of Anopheles mos-
quitoes are to be sustained and eventually expanded, 
the identification of new, environmentally safe, cost-
effective larvicides is critical. The results of this investi-
gation, combined with our past findings [25–27], suggest 
that yeast-based larvicides may represent a promising 
new tool for control of Anopheles mosquitoes. To date, 
we have shown that these larvicides induce high lev-
els of An. gambiae mortality, and it will be interesting 
to expand our laboratory analyses to additional Anoph-
eles species, particularly given that the sema.460 target 
site is conserved in most available anopheline genome 
sequences (Additional file 2: Table S1). It will also be crit-
ical to expand formulation development so that optimal 
formulations are developed for each Anopheles species. 
Long-lasting FourStar™ briquette larvicides significantly 
reduced mean densities of both indoor- and outdoor-
biting malaria vector mosquitoes in Western Kenya [64]. 
More recently, long-lasting LL3 and FourStar briquettes 
were found to significantly reduce immature densities of 
An. gambiae and An. funestus, with significant reductions 
observed for three months post-application. For habitats 
prone to overflow or water flow resulting from heavy 
rains, these briquettes were attached to poles with loose 
thin strings at the water margins [65]. It may be possible 
to develop similar formulations of yeast-based larvicides.
Conclusions
The results of this study have demonstrated that 
sema.460, a yeast interfering RNA larvicide with a target 
site conserved in Ae. aegypti, Ae. albopictus, Cx. quinque-
fasciatus, as well as a variety of Anopheles spp. mosqui-
toes, functions as a broad-based mosquito insecticide 
(Figs.  1, 2, 4). The sema.460 target site is not found to 
be conserved in humans or in the available genomes of 
other non-target organisms, including insects other than 
mosquitoes (Additional file  2: Table  S1). The activity of 
sema.460 was confirmed in laboratory trials that were 
designed to more closely simulate field conditions, as 
well as in outdoor semi-field trials (Fig. 3). This study, in 
conjunction with our past work [25–27], indicates that S. 
cerevisiae could serve as an excellent system for produc-
tion of interfering RNA larvicides, as well as the delivery 
of these larvicides to a variety of different species of mos-
quito larvae. These yeast larvicides may offer a new bio-
rational means of controlling a variety of disease vector 
mosquito species and combating insecticide resistance. 
Moreover, development of sema.460, a broad-based yeast 
interfering RNA mosquito larvicide, has furthered our 
ongoing efforts [25–27] to build an arsenal of interfering 
RNA pesticides that could be used to combat insecticide 
resistance that emerges from point mutations in the tar-
get site of any single insect target gene.
Additional files
Additional file 1. Sequences of sema.460 and Control transgenes. The 
sequences of the sema.460 and control shRNA‑encoding DNA cassettes 
used to generate pRS 426 plasmid clones are provided. Sequences of the 
sema.460 and control shRNA expression cassettes that were stably inte‑
grated at the ura3 and trp1 loci in the S. cerevisiae genome are also shown.
Additional file 2: Table S1. Assessment of sema.460 target site conserva‑
tion. The 21 bp sequence targeted by sema.460 was used as a blastn 
query against all Aedes, Anopheles and Culex genomes in Vectorbase. 
Mosquito species bearing perfectly conserved target sequences are 
listed; the gene numbers (if known) or scaffold locations (s) correspond‑
ing to each match are indicated. The sema.460 target sequence was also 
used as an input for NCBI blastn searches conducted on the indicated 
taxonomic groups; corresponding taxonomic identification numbers 
(TaxIDs) are listed for each group. As of December 2018, searches against 
all sequences in the blast database did not uncover any perfect matches 
to the sema.460 target sequence outside of the indicated disease vector 
mosquito species.
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